Logo Asphalion

HORIZON 2020 PROJECT | Tumor-LN-oC FOLLOW-UP MEETING

The meeting, which was attended by all 11 partners with representatives from microfluidics, cell biology, cancer biology, physics, computer programming and regulatory affairs fields, was the first presential meeting of the Tumor-LN-oC consortium, allowing the participants to meet in person after six months of working together.

The meeting, which was attended by all 11 partners with representatives from microfluidics, cell biology, cancer biology, physics, computer programming and regulatory affairs fields, was the first presential meeting of the Tumor-LN-oC consortium, allowing the participants to meet in person after six months of working together.
November 22, 2021

Asphalion experts Marta Morales and Mariana Gómez participated in the 6-month follow-up meeting of Horizon 2020 project Tumor-LN-oC that took place in Athens last week. The meeting, which was attended by all 11 partners with representatives from microfluidics, cell biology, cancer biology, physics, computer programming and regulatory affairs fields, was the first presential meeting of the Tumor-LN-oC consortium, allowing the participants to meet in person after six months of working together.

The EU-funded Tumor-LN-oC project proposes the development and validation of a TRL 5 tumor-lymph node-on-chip (Tumor-LN-oC) platform composed of 3D tissue models and microfluidic chips which will connect surgically removed human primary tumors and LN tissue from the same lung cancer patient. This will serve as a “biological twin” of the patient and will allow to study the interaction of primary tumors with LNs for individual patients.

For a complete overview about the project, we invite you to have a look at the press release: https://tumor-ln-oc.eu/wp-content/uploads/2021/09/Tumor-LN-oC-press-release.pdf

For further information you can contact us at: info@asphalion.com

 

Search News & Events

  • Filter by category

Share

Related news and events

In2Sight | 4th annual meeting 3RS congress

At ASPHALION, we are part of the IN2SIGHT consortium, an EU-funded project, and we are delighted to be currently participating in the 4th annual meeting

Course | Regulatory aspects of vaccine development

TRANSVAC2 supported innovation for both prophylactic and therapeutic vaccine development by providing high-quality technical services across four different service platforms: Technology (for process development and GMP production), Immunocorrelates & Systems Biology, Animal models, and support for Clinical Trials. TRANSVAC also offered training courses to provide fundamental and advanced knowledge on a wide-range of vaccine development-related topics.

ASPHALION HIGHLIGHTS Q2 2023

A lot of things have happened during these past three months. We received an award from AEFI as most engaged Company with its employees’ traning;

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting